Top News

Gilead Sciences Buys Calistoga Pharmaceuticals

Foster City-based Gilead Sciences said today that it is acquiring Calistoga Pharmaceuticals, a Seattle developer of inflammatory, autoimmune, and cancer drugs. Gilead will pay $375M plus up to $225M in earnout for Calistoga. Calistoga was venture backed by Alta Partners, Amgen Ventures, Frazier Healthcare Ventures, Latterell Venture Partners, Lilly Bioventures, Quogue Capital, Three Arch Partners, and others.


 

Marketplace


blog comments powered by Disqus
 

Latest Headlines

Browse Issues